Iterum Therapeutics plc — Director's Dealing 2019

May 29, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2019-05-24

Reporting Person: HEALY JAMES (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-24	Ordinary Shares	M	6154	—	Acquired	6154	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-24	Restricted Stock Units	$	M	6154	Disposed		Ordinary Shares (6154)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	1726514	Indirect

Footnotes

F1: Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units.

F2: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. The reporting person disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

F3: On May 24, 2018, the reporting person was granted an award of 6,154 restricted stock units, which vested on May 24, 2019.